Rx or OTC for generic desloratadine
This article was originally published in The Tan Sheet
Executive Summary
Generic pharmaceutical firm Mylan may market desloratadine tablets (5 mg) in the U.S. beginning in July 2012 in direct competition with Schering-Plough's Clarinex allergy medication, according to a patent litigation settlement announced April 8. Pending FDA's approval of Pittsburgh-based Mylan's abbreviated new drug application, the firm can market the tablets as Rx or OTC depending on the status at the time for Clarinex, which is considered a likely switch candidate (1"The Tan Sheet" Feb. 4, 2008, p. 5). Sales of desloratadine tablets (5 mg) reached $284 million in the U.S. during 2008, according to IMS Health
You may also be interested in...
Morgan Stanley Analysts Handicap Potential Switches In Near Future
With the potential to cash in on up to $10 billion in branded sales in the next five years, a number of prescription drugs are positioned to break into the OTC market by 2012, Morgan Stanley analysts say
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.